Thomas Weisel Starts Obagi Medical (OMPI) at Market Weight
More News related to OMPI
- Canaccord Adams Maintains a 'Buy' on Obagi Medical Products (OMPI); Raises PT
- OBAGI Medical (OMPI) Posts Q3 EPS of $0.14, In-Line with Street; Guides
- Obagi Medical Products Reports Third Quarter 2009 Earnings
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Obagi Medical Products to Report Third Quarter 2009 Financial Results and Host a Conference Call on November 5, 2009
More News related to New Coverage
- Jo-Ann Stores (JAS) Falls As Investors Yawn at In-Line Results and Guidance
- Dynamex (DDMX) Posts Q1 EPS of $0.31, Tops by 5c
- Dynamex (DDMX) Reports Q1 EPS of $0.31, Beats by 5c
- Aeropostale (ARO) Delivers In 3Q, But Important 4Q Guidance Not Rosy Enough
- SeaChange (SEAC) Reports Solid Q3 Results; Guides Q4, FY11
Thomas Weisel starts Obagi Medical (Nasdaq: OMPI) at Market Weight with a $7 price target.
Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
-0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
